Working… Menu

Alvocidib Biomarker-driven Phase 2 AML Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02520011
Recruitment Status : Recruiting
First Posted : August 11, 2015
Last Update Posted : May 23, 2019
Information provided by (Responsible Party):
Tolero Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 2020